Middle East Pharmaceutical Industries Co. (4016.SR)
SAR 120.2
(-0.5%)
SAR 120.2
(-0.5%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 92.65 Million | 64.63 Million | 40.71 Million | 44.41 Million | 58.59 Million |
| Net Income | 65.82 Million | 59.45 Million | 66.28 Million | 72.81 Million | 54.05 Million |
| Depreciation & Amortization | 11.92 Million | 10.62 Million | 9.56 Million | 8.86 Million | 8.68 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | 20.22 Million | -11.62 Million | -39.31 Million | -42.95 Million | -8.56 Million |
| Other non-cash items | -5.32 Million | 36.92 Million | 63.1 Million | 62.86 Million | 24.46 Million |
| Investing Cash Flow | -30.83 Million | -20.2 Million | -24.8 Million | -62.45 Million | -15.81 Million |
| Investments in PPE | -20.83 Million | -20.6 Million | -24.67 Million | -39.57 Million | -15.99 Million |
| Acquisitions | 136.8 Thousand | 406.18 Thousand | 44.2 Thousand | -165.89 Thousand | 184.7 Thousand |
| Investment purchases | - | - | -166.49 Thousand | -22.71 Million | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | -9.99 Million | -10.62 Million | -9.36 Million | -29.45 Million | - |
| Financing Cash Flow | -70.5 Million | -39.68 Million | -12.81 Million | 13.83 Million | -31.11 Million |
| Debt repayment | -6.33 Million | -2.06 Million | -24.38 Million | -50.09 Million | -7.16 Million |
| Dividends payments | -36 Million | -36.34 Million | -37.2 Million | -36.26 Million | -23.95 Million |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - |
| Other Financing Activities | -28.17 Million | -1.27 Million | - | - | - |
| Accounts receivables | -2.44 Million | 12.66 Million | -54.5 Million | 2.4 Million | -7.69 Million |
| Accounts payables | -9.91 Million | 5.22 Million | 6.52 Million | -540.59 Thousand | 1.48 Million |
| Inventory | 12.44 Million | -27.37 Million | 8.18 Million | -41.3 Million | 3.54 Million |
| Other working capital | 10.21 Million | -2.12 Million | 471.3 Thousand | -3.51 Million | -5.89 Million |
| Cash at beginning of period | 23.79 Million | 19.03 Million | 15.92 Million | 20.13 Million | 8.46 Million |
| Cash at end of period | 15.1 Million | 23.79 Million | 19.03 Million | 15.92 Million | 20.13 Million |
| Capital Expenditure | -20.83 Million | -20.6 Million | -24.67 Million | -39.57 Million | -15.99 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -8.68 Million | 4.75 Million | 3.11 Million | -4.21 Million | 11.66 Million |
| Free Cash Flow | 71.82 Million | 44.03 Million | 16.03 Million | 4.84 Million | 42.59 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 21.8 Million | 9.36 Million | 24.13 Million | 65.82 Million | 24.13 Million | 18.04 Million |
| Depreciation & Amortization | 3.49 Million | 3.3 Million | 1.94 Million | 11.92 Million | 1.94 Million | 1.87 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -28.3 Million | 8.94 Million | 8.38 Million | 7.07 Million | 8.38 Million | 1.65 Million |
| Other non-cash items | 13.87 Million | 9.51 Million | -3.25 Million | 27.25 Million | -3.25 Million | -11.01 Million |
| Investing Cash Flow | -3.96 Million | -7.26 Million | -9.97 Million | -30.83 Million | -9.97 Million | -5.76 Million |
| Investments in PPE | -1.51 Million | -4.98 Million | -7.37 Million | -30.97 Million | -7.37 Million | -3.13 Million |
| Acquisitions | - | - | - | 136.8 Thousand | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -2.44 Million | -2.28 Million | -2.59 Million | -9.99 Million | -2.59 Million | -2.63 Million |
| Financing Cash Flow | -19.8 Million | -4.44 Million | -18.61 Million | -66.17 Million | -18.61 Million | -11.91 Million |
| Debt repayment | -1.58 Million | -1.58 Million | - | -25.19 Million | - | -1.58 Million |
| Dividends payments | - | - | -9 Million | -36 Million | -9 Million | -10.09 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -18.21 Million | -2.86 Million | -9.61 Million | -4.98 Million | -9.61 Million | -237.33 Thousand |
| Accounts receivables | -5.46 Million | 3.3 Million | -2.92 Million | -2.44 Million | -2.92 Million | - |
| Accounts payables | 13.18 Million | 6.08 Million | - | -9.91 Million | - | - |
| Inventory | -17.37 Million | 465.49 Thousand | 9.14 Million | 12.44 Million | 9.14 Million | -1.28 Million |
| Other working capital | -5.45 Million | 5.17 Million | 2.16 Million | 6.98 Million | 2.16 Million | 2.93 Million |
| Cash at beginning of period | 34.53 Million | 9.85 Million | - | 23.79 Million | - | 16.97 Million |
| Cash at end of period | 21.63 Million | 34.53 Million | 2.62 Million | 15.1 Million | 2.62 Million | 9.85 Million |
| Capital Expenditure | -1.51 Million | -4.98 Million | -7.37 Million | -30.97 Million | -7.37 Million | -3.13 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -12.9 Million | 24.67 Million | 2.62 Million | -8.68 Million | 2.62 Million | -7.11 Million |
| Free Cash Flow | 9.34 Million | 26.15 Million | 23.83 Million | 57.35 Million | 23.83 Million | 7.42 Million |
INDIAMART
FCN
PSN
GRINFRA
CYBQF
INMD